Archon Biosciences Emerges from Stealth with $20M to Create Tiny ‘Antibody Cages’

Archon Biosciences, a pioneering biotech company, has emerged from stealth with $20M in seed funding. Leveraging AI-driven computational protein design, Archon’s Antibody Cages (AbCs) aim to unlock therapeutic targets previously beyond reach. This cutting-edge platform, co-invented by Nobel Laureate Dr. David Baker and fellow scientists from Institute for Protein Design, University of Washington, represents a breakthrough in novel protein creation.